Topiramate for migraine prevention: a randomized controlled trial.

By J. Brandes, J. Saper, M. Diamond, J. Couch, D. Lewis, J. Schmitt, W. Neto, S. Schwabe, D. Jacobs. Journal of the American Medical Association (JAMA), 2004

677 citations recorded by the source corpus.

Subfields: Neurology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/d79eac1447bb4a516974e598d75702593d76b0e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. P. Goadsby
2. Arne May

In Psychiatry and Mental health

1. Arne May
2. P. Goadsby

Citations in the corpus

• EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force (2009, background): “Valproic acid in a dose of at least 600 mg [99–102] and topiramte in a dose between 25 and 100 mg [103–106] are the two anti-epileptic drugs with evidence of efficacy in more than one placebo-controlled trial.”